The facility, located in Dessau, Germany, will go back to producing Takeda’s dengue vaccine candidate after a three-month period.
Takeda has agreed to help manufacture three different COVID-19 vaccines. The drugmaker has already begun manufacturing Moderna and Novavax vaccines to provide rapid and sustained COVID-19 vaccine access in Japan.
More articles on pharmacy:
No link between AstraZeneca vaccine, blood clots, WHO says, despite countries halting use
HHS allows retired pharmacists, pharmacy interns to give COVID-19 vaccinations
Gilead, Merck co-developing long-acting HIV treatment
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
